AF
ITOS

Amalgamated Financial’s iTeos Therapeutics ITOS Stock Holding History

Amalgamated Financial’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$288K Buy
+8,953
New +$325K ﹤0.01% 1751

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Amalgamated Financial's ITOS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in iTeos Therapeutics (ITOS) in Q1 2022: 8,953 shares worth $288K. The stake represents ﹤0.01% of the portfolio and ranks #1751 among its holdings.

159 funds tracked by Wall St. Rank hold ITOS as of Q1 2022.

  • Amalgamated Financial held 8,953 shares of iTeos Therapeutics worth $288K as of Q1 2022.
  • iTeos Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • iTeos Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1751 holding.
  • 159 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.